Late human studyUT Health San Antonio / ARPA-H PROSPR
ARPA-H VITAL-H healthspan drug trial
If the effect in people is large enough, this could become a medicine used to slow one or more processes that drive age-related decline.
- Can you act?
- Sometimes through a clinical study. Access depends on the study locations and eligibility rules.
- Best current outlook
- Roughly 2–5 years to broader access if the study succeeds and regulators agree.
See what this could mean for you →Human studyLyGenesis
LyGenesis ectopic liver regeneration
This could keep someone alive and healthier when an organ is failing by repairing it, supporting it or replacing it.
- Can you act?
- Sometimes through a clinical study. Places are usually limited and aimed at a specific condition or group.
- Best current outlook
- Roughly 3–7 years to broader access if results remain positive.
See what this could mean for you →Human studyTransposon Therapeutics
Transposon TPN-101 LINE-1 programme
If the effect in people is large enough, this could become a medicine used to slow one or more processes that drive age-related decline.
- Can you act?
- Sometimes through a clinical study. Places are usually limited and aimed at a specific condition or group.
- Best current outlook
- Roughly 3–7 years to broader access if results remain positive.
See what this could mean for you →Human studyUnited Therapeutics / Miromatrix
United Therapeutics miroliverELAP liver support
This could keep someone alive and healthier when an organ is failing by repairing it, supporting it or replacing it.
- Can you act?
- Sometimes through a clinical study. Places are usually limited and aimed at a specific condition or group.
- Best current outlook
- Roughly 3–7 years to broader access if results remain positive.
See what this could mean for you →Early human studyBioAge Labs
BioAge BGE-102 metabolic-ageing programme
If the effect in people is large enough, this could become a medicine used to slow one or more processes that drive age-related decline.
- Can you act?
- Only through a small early study, when recruitment is open and you meet the eligibility rules.
- Best current outlook
- Often 5–10 years from broad availability, if safety and later studies succeed.
See what this could mean for you →Early human studyBiVACOR
BiVACOR total artificial heart
This could keep someone alive and healthier when an organ is failing by repairing it, supporting it or replacing it.
- Can you act?
- Only through a small early study, when recruitment is open and you meet the eligibility rules.
- Best current outlook
- Often 5–10 years from broad availability, if safety and later studies succeed.
See what this could mean for you →Early human studyCellvie
Cellvie therapeutic mitochondria
If the effect in people is large enough, this could become a medicine used to slow one or more processes that drive age-related decline.
- Can you act?
- Only through a small early study, when recruitment is open and you meet the eligibility rules.
- Best current outlook
- Often 5–10 years from broad availability, if safety and later studies succeed.
See what this could mean for you →Early human studyeGenesis
eGenesis EGEN-2784 xenokidney
This could keep someone alive and healthier when an organ is failing by repairing it, supporting it or replacing it.
- Can you act?
- Only through a small early study, when recruitment is open and you meet the eligibility rules.
- Best current outlook
- Often 5–10 years from broad availability, if safety and later studies succeed.
See what this could mean for you →Early human studyJunevity
Junevity transcription-factor medicines
If the effect in people is large enough, this could become a medicine used to slow one or more processes that drive age-related decline.
- Can you act?
- Only through a small early study, when recruitment is open and you meet the eligibility rules.
- Best current outlook
- Often 5–10 years from broad availability, if safety and later studies succeed.
See what this could mean for you →Early human studyLife Biosciences
Life Biosciences ER-100 optic-nerve programme
If the project succeeds, it could add another practical route to prevent, delay or repair age-related decline.
- Can you act?
- Only through a small early study, when recruitment is open and you meet the eligibility rules.
- Best current outlook
- Often 5–10 years from broad availability, if safety and later studies succeed.
See what this could mean for you →Early human studyLIfT BioSciences
LIfT BioSciences neutrophil therapy
This could help an older immune system respond better to infections, vaccines and damaged cells.
- Can you act?
- Only through a small early study, when recruitment is open and you meet the eligibility rules.
- Best current outlook
- Often 5–10 years from broad availability, if safety and later studies succeed.
See what this could mean for you →Early human studyBoston University
New England Centenarian Study
If the project succeeds, it could add another practical route to prevent, delay or repair age-related decline.
- Can you act?
- Only through a small early study, when recruitment is open and you meet the eligibility rules.
- Best current outlook
- Often 5–10 years from broad availability, if safety and later studies succeed.
See what this could mean for you →Early human studyNewLimit
NewLimit epigenetic reprogramming
If it works, this approach could restore healthier behaviour in ageing cells or repair biological damage that the body no longer fixes well on its own.
- Can you act?
- Only through a small early study, when recruitment is open and you meet the eligibility rules.
- Best current outlook
- Often 5–10 years from broad availability, if safety and later studies succeed.
See what this could mean for you →Early human studyNYU Langone Health
NYU Langone xenotransplant research
This could keep someone alive and healthier when an organ is failing by repairing it, supporting it or replacing it.
- Can you act?
- Only through a small early study, when recruitment is open and you meet the eligibility rules.
- Best current outlook
- Often 5–10 years from broad availability, if safety and later studies succeed.
See what this could mean for you →Early human studyAgelessRx and academic collaborators
PEARL rapamycin longevity study
If the effect in people is large enough, this could become a medicine used to slow one or more processes that drive age-related decline.
- Can you act?
- Only through a small early study, when recruitment is open and you meet the eligibility rules.
- Best current outlook
- Often 5–10 years from broad availability, if safety and later studies succeed.
See what this could mean for you →Early human studyRubedo Life Sciences
Rubedo RLS-1496 senescent-cell programme
If it works, it could remove or quiet damaged cells that build up with age and disturb the healthy cells around them.
- Can you act?
- Only through a small early study, when recruitment is open and you meet the eligibility rules.
- Best current outlook
- Often 5–10 years from broad availability, if safety and later studies succeed.
See what this could mean for you →Early human studyUnited Therapeutics and Revivicor
United Therapeutics xenokidney programme
This could keep someone alive and healthier when an organ is failing by repairing it, supporting it or replacing it.
- Can you act?
- Only through a small early study, when recruitment is open and you meet the eligibility rules.
- Best current outlook
- Often 5–10 years from broad availability, if safety and later studies succeed.
See what this could mean for you →Early human studyVandria
Vandria mitophagy medicines
If the effect in people is large enough, this could become a medicine used to slow one or more processes that drive age-related decline.
- Can you act?
- Only through a small early study, when recruitment is open and you meet the eligibility rules.
- Best current outlook
- Often 5–10 years from broad availability, if safety and later studies succeed.
See what this could mean for you →